Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
企業コードBBNX
会社名Beta Bionics Inc
上場日Jan 30, 2025
最高経営責任者「CEO」Mr. Sean Saint
従業員数291
証券種類Ordinary Share
決算期末Jan 30
本社所在地11 Hughes
都市IRVINE
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号92618
電話番号19494277785
ウェブサイトhttps://www.betabionics.com
企業コードBBNX
上場日Jan 30, 2025
最高経営責任者「CEO」Mr. Sean Saint
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし